SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback